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Abstract 
Warfarin is a commonly used anticoagulant drug and is a derivate of coumarin.  Cytochrome 
P450 2C9 (CYP2C9) plays the key role in transformation of coumarin and thus, influences 
determination of warfarin dosage.  A number of factors including dietary compounds such as 
sesamin, caffeic acid and ferulic acids can regulate the activity of CYP2C9. The present study 
tested the hypothesis that sesamin, episesamin, caffeic acid and ferulic acid decreases the rate 
of warfarin 7-hydroxylation via inhibition of hepatic CYP2C9. The experiments were 
conducted on hepatic microsomes from human donors. It was demonstrated that the rate of 7-
hydroxylation of warfarin was significantly decreased in the presence of sesamin in the range 
of concentrations from 5 to 500 nM, and was not affected by episesamin, caffeic acid and 
ferulic acid in the same range of concentrations. The kinetic analysis indicated non-
competitive type of inhibition by sesamin with Ki = 202±18 nM. In conclusion, the results of 
our in vitro study revealed that sesamin was able to inhibit formation of a major metabolite of 
warfarin, 7-hydroxywarfarin. The potentially negative consequences of the consumption of 
high amounts of sesamin-containing food or dietary supplements in warfarin-treated patients 
need to be further studied. 
 
Keywords: S-7-hydroxywarfarin; cytochrome P450; in vitro; food-drug interactions; 
detoxification 
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1. Introduction  
Warfarin, a derivative of coumarin, is an oral anticoagulant drug to manage 
thromboembolic disease by preventing the synthesis of vitamin K-dependent proteins 
involved in blood coagulation, predominantly factors II, VII, IX and X (Rice et al., 2003). It is 
clinically used as a racemic mixture of equal amounts of S and R stereoisomers, with S-
warfarin having 3-5 times greater anticoagulation potency compared to R-warfarin. The 
predominant fate of S-warfarin biotransformation in humans is 7-hydroxylation of the 
coumarin ring by cytochrome P450 (CYP) 2C9 (Yasuda et al., 2010). This metabolic 
transformation of warfarin to 7-hydroxywarfarin by CYP2C9 is specific only for S-warfarin. 
Therefore, polymorphisms in CYP2C9 have effect on the rate of coumarin biotransformation 
and thus are the major determinants of warfarin dosage requirement (Cavallari et al., 2011). 
Because of a narrow therapeutic index of warfarin and its predisposition to drug interactions, 
careful studies are required to identify foods or food components with potential to interact 
with warfarin metabolism, and explain biochemical mechanisms causing these interactions 
(Leite et al., 2016). Nowadays, at least 58 plants including ginger, garlic and St. John's wort 
are known to interact with warfarin metabolism (Leite et al., 2016). The majority of such 
interactions are due to inhibition of expression or activity of CYP2C9 or other enzymes 
involved in warfarin metabolism (Di Minno et al., 2017). Additionally, clinical factors, such 
as weight, age, smoking, concomitant use of other drugs that interfere with warfarin 
metabolism, are known to affect warfarin dose requirements and cause the difficulties of 
anticoagulant management (Gage et al., 2004). The effect of vitamin K intake on warfarin 
anticoagulation is a classic example of warfarin-food interactions. Therefore, it is of 
increasing interest to development of new vitamin K-independent coagulation factor 
inhibitors which lack food compound interactions and can replace warfarin. Yet, warfarin 
remains nowadays the most commonly prescribed oral anticoagulant.  
*Manuscript showing all track changes
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Sesame (Sesamun indicum L.) is an important food source in many countries and is often 
associated with decreased risk of cardiovascular diseases (Namiki et al., 2007). It has also 
been suggested to have anti-oxidant and anti-inflammatory properties (Kamal-Eldin et al., 
2011). These properties are mainly attributed to the lignans in sesame-based products 
sesamin, sesamol and sesamolin. The highest observed concentration (Cmax) of sesamin in 
human plasma was reported to be 100 nM after consumption of a single dose of sesame seeds 
(50 g) (Peñalvo et al., 2005), and was 8 nM after intake of 50 mg of sesamin supplement 
containing an equal amount of sesamin and episesamin (Tomimori et al., 2013). The 
maximum concentration of sesamin in the human liver following a 50 mg oral administration 
was estimated to be 130 nM (Yasuda et al., 2015).  
Similarly to warfarin, sesamin is metabolized by CYP2C9 and also act as a mechanism-
based inhibitor of CYP2C9 activity in human liver microsomes (Yasuda et al., 2010). 
Although sesamin was demonstrated not to interfere with warfarin metabolism in rats (Yasuda 
et al., 2015), the safety of sesamin with respect to warfarin–sesamin interactions in humans 
are not yet clarified. 
Caffeic acid, the major representative of hydroxycinnamic acids, is one of the most 
common phenolic acids found in coffee, fruits and dietary supplements. Caffeic acid was 
found to be a potent competitive inhibitor of CYP2C9 (Rastogi et al., 2014), the enzyme 
which mediates warfarin metabolism. Ferulic acid, which is a metabolite of caffeic acid, is 
commonly found in rice, wheat, oats, grasses, flowers, fruits and nuts, and was also recently 
shown to interact with warfarin (Li et al., 2016).  
Although warfarin has been widely investigated, particularly in its relationship to vitamin 
K intake, the effects of commonly occurring food compounds on warfarin metabolism remain 
largely uncharacterized. It is known that the efficacy of warfarin is mainly affected when 
metabolism of S-warfarin is altered. Thus, in the present study we tested the hypothesis that 
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sesamin, caffeic and ferulic acid decrease the rate of warfarin 7-hydroxylation through 
inhibition of human hepatic CYP2C9 in vitro. Effect of episesamin on warfarin metabolism 
was also investigated, as the same amount of both, sesamin and its geometric isomer 
episesamin is present in sesame oil and dietary supplement. 
 
2. Materials and methods 
2.1. Materials and reagents 
Warfarin, 7-hydroxywarfarin, episesamin, caffeic acid, ferulic acid, reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH), dimethylsulfoxide (DMSO) and 
trichloroacetic acid (TCA) were obtained from Sigma-Aldrich (Steinheim, Germany). 
Sesamin was obtained from Kebiotech (Beijing, China). Acetonitrile and methanol of HPLC 
grade were purchased from Merck (Darmstadt, Germany). A stock solutions (20 mM) of 
sesamin, episesamin, caffeic and ferulic acids were prepared in dimethyl sulfoxide (DMSO). 
Human liver microsomes pooled from individual donors of both genders were purchased from 
three companies, GIBCO (Stockholm, Sweden, Cat.HMMCPL, lot. PL050B-B), inVitro 
(Stockholm, Sweden, Product X008070, lot SPL), and Sigma-Aldrich (Steinheim, Germany, 
pooled lots SLBM1949V and SLBK2748V). The pool from GIBCO contained microsomes 
from 20 donors and the pool from inVitro - from 150 donors. The number of donors in the 
pool obtained from Sigma-Aldrich was not specified. The samples from three purchasing 
source were selected because we have previously observed between-manufacture differences 
in the activity of selected CYPs (unpublished data). The protein concentration in all human 
liver microsomes was 20 mg/mL. 
 
2.2. Inhibition study  
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The rate of warfarin 7-hydroxylation was determined as described previously (Yamaori et 
al., 2015). Concentrations of 7-hydroxywarfarin were determined by interpolation of standard 
curve produced with authentic standards. 
Sesamin, episesamin, caffeic and ferulic acid were added into the incubation mixture at 
final concentrations of 5, 10, 50, 100, and 500 nM. The amount of 7-hydroxywarfarin formed 
in the presence of sesamin, episesamin, caffeic or ferulic acid was compared with control 
incubations containing corresponding amounts of DMSO. All inhibitors were added before 
the addition of warfarin. To test reversibility of the inhibition, the test inhibitors were first 
pre-incubated with human liver microsomes for 30 min at 37 °C with NADPH but without 
warfarin. After this, warfarin was added and the mixture was incubated for further 60 min. 
The two control incubations (one without a pre-incubation step and another with pre-
incubation in absence of NADPH) were run in parallel. An experiment with a known 
competitive inhibitor of CYP2C9 sulfaphenazole was conducted as a positive control using 
0.1, 0.5, 12.5 and 50 µM of sulfaphenazole without pre-incubation step (Bourrié  et al., 1996). 
 
2.3. Data analysis 
The IC50 values (concentration causing 50% reduction of control activity) for sesamin 
were determined by linear regression analysis from plotting the logarithm of inhibitor 
concentration vs percentage of activity remaining after inhibition (GraphPad Prism version 
7.03 for Windows, GraphPad Software, San Diego California, USA). Inhibition constant (Ki) 
was determined using range of sesamin (10 and 50 nM) and warfarin (5 to 200 µM) 
concentrations. Michaelis-Menten constant (Km) and maximum velocity (Vmax) were 
calculated using a non-linear regression analysis. Enzyme kinetic equations for competitive, 
non-competitive, uncompetitive and mixed inhibition type were compared using extra least 
sum-of-squares F test. 
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3. Results and discussion 
As expected, sulfaphenazole inhibited CYP2C9-mediated warfarin 7-hydroxylation in a 
concentration-dependent manner (Fig. 1). Sesamin inhibited warfarin 7-hydroxylation in all 
the tested concentrations, while its geometric isomer episesamin had no effect (Fig. 2). The 
lowest amount of 7- hydroxywarfarin was formed in the presence of 500 nM of sesamin 
(mean ± standard deviation; 46 ± 8.5 %). Including a pre-incubation step did not increase 
sesamin inhibitory effect as indicated by unaltered IC50 value (IC50 = 202 nM and 193 nM in 
the absence and presence of pre-incubation step, respectively). More detailed kinetic analysis 
indicated non-competitive type of inhibition (Fig. 3), with Ki = 202 ± 18 nM, a decrease in 
Vmax from 66.7 ± 8.9 to 48.6 ± 5.0 pmol/min/mg and unaltered Km = 7.2 ± 2.1 µM. Since 
warfarin has a narrow therapeutic index, its inhibition might have serious and difficult to 
predict consequences. 
It is well documented that warfarin pharmacotherapy can be affected by food or dietary 
supplements in several ways (Nutescu et al., 2006). One example is inhibition of the 
anticoagulant effect of warfarin by the dietary vitamin K. Since warfarin function is to reduce 
the activity of vitamin K in blood clotting processes, dietary vitamin K might diminish the 
effect of warfarin (Nutescu et al., 2004; 2006).  However, recent reports provided conflicting 
results (Violi et al., 2016; Choi et al., 2014; Kwon et al., 2010). It was suggested that stable 
dietary intake of vitamin K is more relevant for a reduction in variations of warfarin effect 
compared to previous recommendations to restrict vitamin K when taking warfarin (Violi et 
al., 2016). 
Hepatic S-warfarin metabolism is mediated by CYP. Therefore, potent inhibitors or 
inducers of CYP activity might strongly modify the therapeutic effects of warfarin. The main 
finding of our study was that sesamin, the major fat-soluble lignan in sesame seed, inhibited 
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7-hydroxylation of warfarin with Ki = 202 nM. In the liver, sesamin is metabolized mainly by 
CYP2C9 to produce hydroxylated metabolites (Yasuda et al., 2010). The same enzyme is 
responsible for the formation of 7-hydroxywarfarin from warfarin. Thus, we expected that 
sesamin and warfarin will compete for the active site of the enzyme. Indeed, Yasuda et al.  
(2010) described a competitive inhibition of CYP2C9 by sesamin with the apparent Ki value 
of 24 μM. However, in the present study we observed non-competitive inhibition of warfarin 
metabolism, which means that sesamin binds to CYP2C9 in another place than the active site 
and alter the active site so that it can't bind warfarin. Previously it was suggested that sesamin 
can also act as a mechanism-based inhibition of CYP2C9 activity, estimated as diclofenac 
hydroxylation, with the apparent Ki value of 22 μM and Kinact value of 0.13 min
−1
, 
respectively (Yasuda et al., 2010). It is obvious that non-competitive inhibition is less severe 
compared to the mechanism-based because it does not require re-synthesis of inactivated 
enzyme to restore its activity. However, in the present study, sesamin inhibited warfarin 
metabolism at much lower concentrations than in the study of Yasuda et al. (2010). The 
differences in inhibition mode and Ki values observed in the present study and previously 
published results are likely to be due to the use of different substrates. Yasuda et al. (2010; 
2015) analysed diclofenac metabolism to estimate CYP2C9 activity, whilst the present study 
focuses on warfarin metabolism. Interestingly, no interactions between sesamin and 
diclofenac were observed when sesamin was administered to rats in a concentration of 100 
mg/kg body weight (Yasuda et al., 2015), suggesting possible substrate- or species-related 
differences in the regulation of CYP2C9 activity by sesamin. The peak plasma concentration 
of sesamin in human was previously reported to be 100 nM after administration of a single 
dose of sesame seeds containing 170 mg of sesamin (Peñalvo et al., 2005), which is within the 
range of sesamin concentrations at which we observed inhibition of warfarin metabolism. 
Generally, the contents of sesamin in sesame-based food products is highly variable 
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(Moazzami et al., 2007). In refined sesame oils, sesamin concentrations ranged between 118 
and 401 mg/100 g seed (Moazzami et al., 2007). Moreover, sesamin content greatly vary 
between the sesame cultivars depending on genetic variation and geographic location (Wang 
et al., 2013).  Nowadays, consumption of products and cuisines with sesame seeds is steadily 
increasing, and sesamin supplements are considered by consumers as highly healthy. Thus, a 
clinically important interaction with concomitantly administrated warfarin and sesamin might 
be probable and need further investigations.  
Episesamin, a geometric isomer of sesamin, did not affect warfarin metabolism in the 
present study. Differences in biological effects of sesamin and episesamin were observed 
previously in rats. It was found that episesamin increases gene expression and activity of the 
enzymes involved in fatty acid metabolism to a higher degree than sesamin (Kushiro et al., 
2002; Ide et al., 2009). Episesamin differs from sesamin in the three-dimensional structure. 
Moreover, it was shown that episesamin is a poorer substrate of CYP2C9 than sesamin, and is 
also metabolised by CYP1A2 (Yasuda et al., 2012). Thus, the differences in metabolism of 
sesamin and episesamin might be responsible for the divergent effects of these compounds on 
warfarin metabolism. 
In the present study, only direct inhibition of warfarin metabolism by several bioactive 
compounds was considered. However, warfarin metabolism can be altered through the 
activation/inhibition of pregnane X receptor (PXR). Warfarin itself and warfarin-hydroxylated 
racemic metabolites act as activators of PXR, and consequently induce PXR target genes 
including CYP3A4 and CYP2C9 (Rulcova et al., 2010; Miller, 2010). Interestingly, S-
warfarin is a less potent PXR activator compared to R-warfarin (Rulcova et al., 2010).  
Sesamin was demonstrated to act as a PXR-antagonist, causing down-regulation of CYP3A4 
(Lim et al., 2012).  It is likely that sesamin also down-regulates in vivo CYP2C9 expression in 
a similar manner. In the present study, the role of nuclear receptors was not studied as they 
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not present in the model used (isolated microsomes). This aspect will be an aim of future 
study on other in vitro models which contain various nuclear receptors, conjugation enzymes 
and transporters. Our study provides important information on possibility of interactions 
between sesamin and warfarin hepatic metabolism. Thus, sesamin can affect warfarin 
metabolism by multiple mechanisms – directly, as demonstrated in the present study, and 
possibly thought the interaction with PXR. Moreover, CYP2C9-generated 7-hydroxywarfarin 
is also a potent inhibitor of CYP2C9 and limits metabolic capacity of CYP2C9 toward S-
warfarin (Jones 2010). However, physiological significance of this feedback inhibition of 
CYP2C9 requires further investigations. 
Neither caffeic nor ferulic acids affected in vitro warfarin metabolism in the range of 
concentrations from 5 to 500 nM (data not shown). These results agree with the study by 
Appiah-Opong et al. (2007) who found no effect of ferulic acid on CYP2C9 activity. 
Interaction between ferulic acid and pharmacokinetics of warfarin was recently demonstrated 
in a biliary drainage model with healthy rats, but these interactions were suggested to happen 
at the level of enterohepatic circulation of warfarin and were not due to metabolism (Li et al., 
2016). Caffeic acid did not have any effect on warfarin metabolism in the present study, 
although it was previously suggested that caffeic acid inhibits CYP2C9 activity (Rastogi et 
al., 2014). It should be, however, emphasized that the previous in vitro study by Rastogi et al.  
(2014) used high concentrations of caffeic acid (from 0.14 to 100 μM), and the Ki value for 
CYP2C9 was determined in the presence of 1.25, 2.5, 5.0 and 10 µM of caffeic acid. 
 
4. Conclusion 
The results of our in vitro study revealed that sesamin was able to non-competitively inhibit 
formation of a major metabolite of warfarin, 7-hydroxywarfarin. This inhibition was 
characterized by low Ki value of 202 ± 18 nM. The potentially negative consequences of the 
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consumption of high amounts of sesamin-containing food or dietary supplements in warfarin-
treated patients need to be further studied.  
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Figure legends 
Figure 1. Formation of 7-hydroxywarfarin (percentage of control activity) in the presence of 
CYP2C9 inhibitor sulfaphenazole in human liver microsomes. Control activity was 
determined in the absence of sulfaphenazole and was regarded as 100%. Dashed line 
represent 50% of control activity. Data represent mean values and standard error of mean 
(n = 3). 
Figure 2. Formation of 7-hydroxywarfarin (percentage of control activity) in human liver 
microsomes in the presence of sesamin and episesamin. Control activity was determined 
in the absence of sesamin and was regarded as 100%. Dashed line represent 50% of 
control activity. Activities was measured with and without 30 min pre-incubation before 
the addition of warfarin. Data represent mean values and standard error of mean (n = 3). 
Figure 3. Saturation kinetics for warfarin 7-hydroxylation by human liver microsomes in the 
absence and presence of sesamin. Data represent mean values and standard error of mean 
from three microsomal pools. Curves indicate model-generated values using the 
Michaelis-Menten equation. Insert: Lineweaver-Burk plot of warfarin metabolism 
inhibition (non-competitive) by sesamin in human liver microsomes. Data represent mean 
values and standard error of mean (n = 3). 
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1. Introduction  
Warfarin, a derivative of coumarin, is an oral anticoagulant drug to manage 
thromboembolic disease by preventing the synthesis of vitamin K-dependent proteins 
involved in blood coagulation, predominantly factors II, VII, IX and X (Rice et al., 2003). It is 
clinically used as a racemic mixture of equal amounts of S and R stereoisomers, with S-
warfarin having 3-5 times greater anticoagulation potency compared to R-warfarin. The 
predominant fate of S-warfarin biotransformation in humans is 7-hydroxylation of the 
coumarin ring by cytochrome P450 (CYP) 2C9 (Yasuda et al., 2010). This metabolic 
transformation of warfarin to 7-hydroxywarfarin by CYP2C9 is specific only for S-warfarin. 
Therefore, polymorphisms in CYP2C9 have effect on the rate of coumarin biotransformation 
and thus are the major determinants of warfarin dosage requirement (Cavallari et al., 2011). 
Because of a narrow therapeutic index of warfarin and its predisposition to drug interactions, 
careful studies are required to identify foods or food components with potential to interact 
with warfarin metabolism, and explain biochemical mechanisms causing these interactions 
(Leite et al., 2016). Nowadays, at least 58 plants including ginger, garlic and St. John's wort 
are known to interact with warfarin metabolism (Leite et al., 2016). The majority of such 
interactions are due to inhibition of expression or activity of CYP2C9 or other enzymes 
involved in warfarin metabolism (Di Minno et al., 2017). Additionally, clinical factors, such 
as weight, age, smoking, concomitant use of other drugs that interfere with warfarin 
metabolism, are known to affect warfarin dose requirements and cause the difficulties of 
anticoagulant management (Gage et al., 2004). The effect of vitamin K intake on warfarin 
anticoagulation is a classic example of warfarin-food interactions. Therefore, it is of 
increasing interest to development of new vitamin K-independent coagulation factor 
inhibitors which lack food compound interactions and can replace warfarin. Yet, warfarin 
remains nowadays the most commonly prescribed oral anticoagulant.  
*Manuscript for revision (track changes hidden)
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Sesame (Sesamun indicum L.) is an important food source in many countries and is often 
associated with decreased risk of cardiovascular diseases (Namiki et al., 2007). It has also 
been suggested to have anti-oxidant and anti-inflammatory properties (Kamal-Eldin et al., 
2011). These properties are mainly attributed to the lignans in sesame-based products 
sesamin, sesamol and sesamolin. The highest observed concentration (Cmax) of sesamin in 
human plasma was reported to be 100 nM after consumption of a single dose of sesame seeds 
(50 g) (Peñalvo et al., 2005), and was 8 nM after intake of 50 mg of sesamin supplement 
containing an equal amount of sesamin and episesamin (Tomimori et al., 2013). The 
maximum concentration of sesamin in the human liver following a 50 mg oral administration 
was estimated to be 130 nM (Yasuda et al., 2015).  
Similarly to warfarin, sesamin is metabolized by CYP2C9 and also act as a mechanism-
based inhibitor of CYP2C9 activity in human liver microsomes (Yasuda et al., 2010). 
Although sesamin was demonstrated not to interfere with warfarin metabolism in rats (Yasuda 
et al., 2015), the safety of sesamin with respect to warfarin–sesamin interactions in humans 
are not yet clarified. 
Caffeic acid, the major representative of hydroxycinnamic acids, is one of the most 
common phenolic acids found in coffee, fruits and dietary supplements. Caffeic acid was 
found to be a potent competitive inhibitor of CYP2C9 (Rastogi et al., 2014), the enzyme 
which mediates warfarin metabolism. Ferulic acid, which is a metabolite of caffeic acid, is 
commonly found in rice, wheat, oats, grasses, flowers, fruits and nuts, and was also recently 
shown to interact with warfarin (Li et al., 2016).  
Although warfarin has been widely investigated, particularly in its relationship to vitamin 
K intake, the effects of commonly occurring food compounds on warfarin metabolism remain 
largely uncharacterized. It is known that the efficacy of warfarin is mainly affected when 
metabolism of S-warfarin is altered. Thus, in the present study we tested the hypothesis that 
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sesamin, caffeic and ferulic acid decrease the rate of warfarin 7-hydroxylation through 
inhibition of human hepatic CYP2C9 in vitro. Effect of episesamin on warfarin metabolism 
was also investigated, as the same amount of both, sesamin and its geometric isomer 
episesamin is present in sesame oil and dietary supplement. 
 
2. Materials and methods 
2.1. Materials and reagents 
Warfarin, 7-hydroxywarfarin, episesamin, caffeic acid, ferulic acid, reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH), dimethylsulfoxide (DMSO) and 
trichloroacetic acid (TCA) were obtained from Sigma-Aldrich (Steinheim, Germany). 
Sesamin was obtained from Kebiotech (Beijing, China). Acetonitrile and methanol of HPLC 
grade were purchased from Merck (Darmstadt, Germany). A stock solutions (20 mM) of 
sesamin, episesamin, caffeic and ferulic acids were prepared in dimethyl sulfoxide (DMSO). 
Human liver microsomes pooled from individual donors of both genders were purchased from 
three companies, GIBCO (Stockholm, Sweden, Cat.HMMCPL, lot. PL050B-B), inVitro 
(Stockholm, Sweden, Product X008070, lot SPL), and Sigma-Aldrich (Steinheim, Germany, 
pooled lots SLBM1949V and SLBK2748V). The pool from GIBCO contained microsomes 
from 20 donors and the pool from inVitro - from 150 donors. The number of donors in the 
pool obtained from Sigma-Aldrich was not specified. The samples from three purchasing 
source were selected because we have previously observed between-manufacture differences 
in the activity of selected CYPs (unpublished data). The protein concentration in all human 
liver microsomes was 20 mg/mL. 
 
2.2. Inhibition study  
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The rate of warfarin 7-hydroxylation was determined as described previously (Yamaori et 
al., 2015). Concentrations of 7-hydroxywarfarin were determined by interpolation of standard 
curve produced with authentic standards. 
Sesamin, episesamin, caffeic and ferulic acid were added into the incubation mixture at 
final concentrations of 5, 10, 50, 100, and 500 nM. The amount of 7-hydroxywarfarin formed 
in the presence of sesamin, episesamin, caffeic or ferulic acid was compared with control 
incubations containing corresponding amounts of DMSO. All inhibitors were added before 
the addition of warfarin. To test reversibility of the inhibition, the test inhibitors were first 
pre-incubated with human liver microsomes for 30 min at 37 °C with NADPH but without 
warfarin. After this, warfarin was added and the mixture was incubated for further 60 min. 
The two control incubations (one without a pre-incubation step and another with pre-
incubation in absence of NADPH) were run in parallel. An experiment with a known 
competitive inhibitor of CYP2C9 sulfaphenazole was conducted as a positive control using 
0.1, 0.5, 12.5 and 50 µM of sulfaphenazole without pre-incubation step (Bourrié  et al., 1996). 
 
2.3. Data analysis 
The IC50 values (concentration causing 50% reduction of control activity) for sesamin 
were determined by linear regression analysis from plotting the logarithm of inhibitor 
concentration vs percentage of activity remaining after inhibition (GraphPad Prism version 
7.03 for Windows, GraphPad Software, San Diego California, USA). Inhibition constant (Ki) 
was determined using range of sesamin (10 and 50 nM) and warfarin (5 to 200 µM) 
concentrations. Michaelis-Menten constant (Km) and maximum velocity (Vmax) were 
calculated using a non-linear regression analysis. Enzyme kinetic equations for competitive, 
non-competitive, uncompetitive and mixed inhibition type were compared using extra least 
sum-of-squares F test. 
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3. Results and discussion 
As expected, sulfaphenazole inhibited CYP2C9-mediated warfarin 7-hydroxylation in a 
concentration-dependent manner (Fig. 1). Sesamin inhibited warfarin 7-hydroxylation in all 
the tested concentrations, while its geometric isomer episesamin had no effect (Fig. 2). The 
lowest amount of 7- hydroxywarfarin was formed in the presence of 500 nM of sesamin 
(mean ± standard deviation; 46 ± 8.5 %). Including a pre-incubation step did not increase 
sesamin inhibitory effect as indicated by unaltered IC50 value (IC50 = 202 nM and 193 nM in 
the absence and presence of pre-incubation step, respectively). More detailed kinetic analysis 
indicated non-competitive type of inhibition (Fig. 3), with Ki = 202 ± 18 nM, a decrease in 
Vmax from 66.7 ± 8.9 to 48.6 ± 5.0 pmol/min/mg and unaltered Km = 7.2 ± 2.1 µM. Since 
warfarin has a narrow therapeutic index, its inhibition might have serious and difficult to 
predict consequences. 
It is well documented that warfarin pharmacotherapy can be affected by food or dietary 
supplements in several ways (Nutescu et al., 2006). One example is inhibition of the 
anticoagulant effect of warfarin by the dietary vitamin K. Since warfarin function is to reduce 
the activity of vitamin K in blood clotting processes, dietary vitamin K might diminish the 
effect of warfarin (Nutescu et al., 2004; 2006).  However, recent reports provided conflicting 
results (Violi et al., 2016; Choi et al., 2014; Kwon et al., 2010). It was suggested that stable 
dietary intake of vitamin K is more relevant for a reduction in variations of warfarin effect 
compared to previous recommendations to restrict vitamin K when taking warfarin (Violi et 
al., 2016). 
Hepatic S-warfarin metabolism is mediated by CYP. Therefore, potent inhibitors or 
inducers of CYP activity might strongly modify the therapeutic effects of warfarin. The main 
finding of our study was that sesamin, the major fat-soluble lignan in sesame seed, inhibited 
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7-hydroxylation of warfarin with Ki = 202 nM. In the liver, sesamin is metabolized mainly by 
CYP2C9 to produce hydroxylated metabolites (Yasuda et al., 2010). The same enzyme is 
responsible for the formation of 7-hydroxywarfarin from warfarin. Thus, we expected that 
sesamin and warfarin will compete for the active site of the enzyme. Indeed, Yasuda et al.  
(2010) described a competitive inhibition of CYP2C9 by sesamin with the apparent Ki value 
of 24 μM. However, in the present study we observed non-competitive inhibition of warfarin 
metabolism, which means that sesamin binds to CYP2C9 in another place than the active site 
and alter the active site so that it can't bind warfarin. Previously it was suggested that sesamin 
can also act as a mechanism-based inhibition of CYP2C9 activity, estimated as diclofenac 
hydroxylation, with the apparent Ki value of 22 μM and Kinact value of 0.13 min
−1
, 
respectively (Yasuda et al., 2010). It is obvious that non-competitive inhibition is less severe 
compared to the mechanism-based because it does not require re-synthesis of inactivated 
enzyme to restore its activity. However, in the present study, sesamin inhibited warfarin 
metabolism at much lower concentrations than in the study of Yasuda et al. (2010). The 
differences in inhibition mode and Ki values observed in the present study and previously 
published results are likely to be due to the use of different substrates. Yasuda et al. (2010; 
2015) analysed diclofenac metabolism to estimate CYP2C9 activity, whilst the present study 
focuses on warfarin metabolism. Interestingly, no interactions between sesamin and 
diclofenac were observed when sesamin was administered to rats in a concentration of 100 
mg/kg body weight (Yasuda et al., 2015), suggesting possible substrate- or species-related 
differences in the regulation of CYP2C9 activity by sesamin. The peak plasma concentration 
of sesamin in human was previously reported to be 100 nM after administration of a single 
dose of sesame seeds containing 170 mg of sesamin (Peñalvo et al., 2005), which is within the 
range of sesamin concentrations at which we observed inhibition of warfarin metabolism. 
Generally, the contents of sesamin in sesame-based food products is highly variable 
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(Moazzami et al., 2007). In refined sesame oils, sesamin concentrations ranged between 118 
and 401 mg/100 g seed (Moazzami et al., 2007). Moreover, sesamin content greatly vary 
between the sesame cultivars depending on genetic variation and geographic location (Wang 
et al., 2013).  Nowadays, consumption of products and cuisines with sesame seeds is steadily 
increasing, and sesamin supplements are considered by consumers as highly healthy. Thus, a 
clinically important interaction with concomitantly administrated warfarin and sesamin might 
be probable and need further investigations.  
Episesamin, a geometric isomer of sesamin, did not affect warfarin metabolism in the 
present study. Differences in biological effects of sesamin and episesamin were observed 
previously in rats. It was found that episesamin increases gene expression and activity of the 
enzymes involved in fatty acid metabolism to a higher degree than sesamin (Kushiro et al., 
2002; Ide et al., 2009). Episesamin differs from sesamin in the three-dimensional structure. 
Moreover, it was shown that episesamin is a poorer substrate of CYP2C9 than sesamin, and is 
also metabolised by CYP1A2 (Yasuda et al., 2012). Thus, the differences in metabolism of 
sesamin and episesamin might be responsible for the divergent effects of these compounds on 
warfarin metabolism. 
In the present study, only direct inhibition of warfarin metabolism by several bioactive 
compounds was considered. However, warfarin metabolism can be altered through the 
activation/inhibition of pregnane X receptor (PXR). Warfarin itself and warfarin-hydroxylated 
racemic metabolites act as activators of PXR, and consequently induce PXR target genes 
including CYP3A4 and CYP2C9 (Rulcova et al., 2010; Miller, 2010). Interestingly, S-
warfarin is a less potent PXR activator compared to R-warfarin (Rulcova et al., 2010).  
Sesamin was demonstrated to act as a PXR-antagonist, causing down-regulation of CYP3A4 
(Lim et al., 2012).  It is likely that sesamin also down-regulates in vivo CYP2C9 expression in 
a similar manner. In the present study, the role of nuclear receptors was not studied as they 
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not present in the model used (isolated microsomes). This aspect will be an aim of future 
study on other in vitro models which contain various nuclear receptors, conjugation enzymes 
and transporters. Our study provides important information on possibility of interactions 
between sesamin and warfarin hepatic metabolism. Thus, sesamin can affect warfarin 
metabolism by multiple mechanisms – directly, as demonstrated in the present study, and 
possibly thought the interaction with PXR. Moreover, CYP2C9-generated 7-hydroxywarfarin 
is also a potent inhibitor of CYP2C9 and limits metabolic capacity of CYP2C9 toward S-
warfarin (Jones 2010). However, physiological significance of this feedback inhibition of 
CYP2C9 requires further investigations. 
Neither caffeic nor ferulic acids affected in vitro warfarin metabolism in the range of 
concentrations from 5 to 500 nM (data not shown). These results agree with the study by 
Appiah-Opong et al. (2007) who found no effect of ferulic acid on CYP2C9 activity. 
Interaction between ferulic acid and pharmacokinetics of warfarin was recently demonstrated 
in a biliary drainage model with healthy rats, but these interactions were suggested to happen 
at the level of enterohepatic circulation of warfarin and were not due to metabolism (Li et al., 
2016). Caffeic acid did not have any effect on warfarin metabolism in the present study, 
although it was previously suggested that caffeic acid inhibits CYP2C9 activity (Rastogi et 
al., 2014). It should be, however, emphasized that the previous in vitro study by Rastogi et al.  
(2014) used high concentrations of caffeic acid (from 0.14 to 100 μM), and the Ki value for 
CYP2C9 was determined in the presence of 1.25, 2.5, 5.0 and 10 µM of caffeic acid. 
 
4. Conclusion 
The results of our in vitro study revealed that sesamin was able to non-competitively inhibit 
formation of a major metabolite of warfarin, 7-hydroxywarfarin. This inhibition was 
characterized by low Ki value of 202 ± 18 nM. The potentially negative consequences of the 
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consumption of high amounts of sesamin-containing food or dietary supplements in warfarin-
treated patients need to be further studied.  
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Figure legends 
Figure 1. Formation of 7-hydroxywarfarin (percentage of control activity) in the presence of 
CYP2C9 inhibitor sulfaphenazole in human liver microsomes. Control activity was 
determined in the absence of sulfaphenazole and was regarded as 100%. Dashed line 
represent 50% of control activity. Data represent mean values and standard error of mean 
(n = 3). 
Figure 2. Formation of 7-hydroxywarfarin (percentage of control activity) in human liver 
microsomes in the presence of sesamin and episesamin. Control activity was determined 
in the absence of sesamin and was regarded as 100%. Dashed line represent 50% of 
control activity. Activities was measured with and without 30 min pre-incubation before 
the addition of warfarin. Data represent mean values and standard error of mean (n = 3). 
Figure 3. Saturation kinetics for warfarin 7-hydroxylation by human liver microsomes in the 
absence and presence of sesamin. Data represent mean values and standard error of mean 
from three microsomal pools. Curves indicate model-generated values using the 
Michaelis-Menten equation. Insert: Lineweaver-Burk plot of warfarin metabolism 
inhibition (non-competitive) by sesamin in human liver microsomes. Data represent mean 
values and standard error of mean (n = 3). 
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